• Microcap stocks outperforming 2020 record highs, currently trading at 40% above 200-day moving average
• SRAX’s Sequire SaaS platform provides public companies with tools to monitor trading activity, provides actionable insights for use in marketing campaigns
• Sequire subscriber base surged to 3 million active traders across 90 public companies since its 2019 inception

Investor interest sent microcap stocks sky-high in 2020, a trend that is continuing well into 2021 with returns on some microcap ETFs surging at several times the rate of comparable large-cap ETFs (https://ibn.fm/Bu86D). As the tide of investor interest continues to flow into microcaps, public companies are leveraging the power of data through Sequire, SRAX’s (NASDAQ: SRAX) investor analytics SaaS platform that unlocks data and insights critical to targeted marketing campaigns in order to engage current traders and attract new investors.

Small caps – companies generally valued between $50 and $300 million – are typically thought to be more volatile and riskier when compared to established companies. Throughout 2020 and so far in 2021, that risk has paid off for investors willing to take a chance on new companies – particularly those included by SRAX subsidiary LD Micro in its North American microcap index which comprises nearly 1200 companies over 14 sectors (https://ibn.fm/m58cx).

“I cannot believe what I’ve seen in the past year,” said LD Micro President Chris Lahiji. “The LD Micro Index has more than tripled from its March 2020 lows. The tiniest public companies were also some of the biggest winners last year, and already year-to-date.”

After surging 20% in 2020, the Russell 2000 continues to outperform its historic highs and is now trading at 40% above its 200-day moving average as retail traders flood the market amid low interest rates and increased fiscal stimulus. The resulting investor interest has left many public companies looking for insights into trading activity to facilitate communications and gauge investor sentiment.

Sequire provides clarity for public companies via access to tools which help them monitor shareholder buying and selling activity while tracking key investors and outstanding warrants. The service also features applications that allow subscribers to publish company-specific news and obtain stakeholder opinions through customized surveys. The platform has experienced staggering growth since its 2019 inception to include over 3 million active retail investors across 90+ public companies (https://ibn.fm/sPoOj).

“We have been discussing the importance of retail investors in public companies since the inception of Sequire,” said SRAX CEO and Founder Christopher Miglino. “It’s the very reason why we built the platform and related tools – to help companies effectively communicate with these investors.”

As the importance of data increases across the digital landscape, SRAX maintains its commitment to build the largest and most reliable opted-in data sets across a broad range of industry verticals. Through its specialized suite of applications and tools, the Company focuses on providing brands and companies across the CPG, luxury, lifestyle and financial spaces with high-quality data that provides critical, actionable insights integral to strategic marketing campaigns.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin
• Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space
• Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired subsidiary, Adelia Therapeutics Inc., has achieved the earn-out milestones outlined for the time period in the contribution agreement between the two companies (https://ibn.fm/c6o2E). That milestone includes the successful synthesis of multiple tryptamine derivatives.

Furthermore, the synthesis of tryptamine derivatives resulted in quantities adequate enough that Adelia could initiate in vitro “Proof of Principle”; establish that an ADME/PK has been completed; and demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the metabolism of a psychedelic tryptamine.

Adelia focuses on developing medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs, which makes the company an idea fit for Cybin, as it leads the way in researching psychedelic treatment options in the mental health space. Adelia’s proprietary development strategy is based on chemical modifications to already known tryptamine derivatives that significantly alter the pharmacokinetic properties of those derivatives without changing their therapeutic potential. The company’s recent milestone is a direct result of this focus and its dedication to seeking to minimize inter-patient variability by better controlling drug metabolism without loss of efficacy.

Cybin’s acquisition of Adelia resulted in Cybin obtaining an extensive intellectual property portfolio and product pipeline that could lead to diversification beyond major depressive disorder (“MDD”) treatments and regimens. Adelia’s three-pillar development strategy includes novel therapeutics, delivery methods and therapeutic regimens focused on improving patient outcomes. The acquisition also results in Cybin gaining psychedelic derivative drug-development candidates, with the first lead compounds expected to enter clinical studies in 2021.

“We are thrilled to join forces with Adelia,” said Cybin CEO Doug Drysdale when announcing the acquisition (https://ibn.fm/T5eIg). “We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects. Adelia’s expertise across multiple molecules and multiple indications, could potentially give Cybin the ability to address gaps across a larger domain.”

The Adelia acquisition also combines two talented teams that share strong patient-first values and track records of innovation in the field of psychedelics. Adelia’s leadership team of accomplished scientists brings invaluable preclinical development experience that complements Cybin’s clinical experience and resources.

Cybin is a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• BRSF working to improve diagnostics by leveraging AI and machine learning
• Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase
• Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.

But BRSF isn’t stopping there.

The company’s goal is to further improve diagnostics by leveraging artificial intelligence (“AI”) and machine learning processes to analyze a database of brain readings to improve diagnosis and treatment of neurological conditions.

The company is using in-house development in order to provide diagnostic interpretation assistance for health-care providers. Currently, a secure cloud-based infrastructure and AI-assisted diagnostic analysis are in the development phase.

BRSF’s remote diagnostic devices that are already in active use will be used to acquire large datasets of neurological information that will be uploaded to the company’s secure cloud technology. These neural networks of data will be used to identify patterns and biomarkers for neurological disease in the near future. Eventually, this data will be integrated with external graph datasets that contain neurological clinical and research data. When that happens, the neural networks will comb the data to detect patterns. Over time the AI will be able to make predictions that will aid neurologists and increase access to complex neuro-diagnostic expertise (https://ibn.fm/3V7Wx).

As more clinical trials and studies are done on neurological conditions, additional data is acquired. On the Neuroscience Information Framework (“NIF”), there are currently over 4,000 databases of neurological information (https://ibn.fm/7pKza). No single neurologist can attempt to evaluate that much data to discover the best treatment for the one patient under their care.

But a computer can. By creating a secure cloud of BRSF’s data that can be integrated with external datasets and using AI with machine learning to filter through the data, neurologists will be able to locate the information needed to best help their patients. The implications of this technology is huge.

An article in Forbes states that “Biomarkers of Longevity integrated with AI and machine learning techniques have the potential to help prevent age-related diseases and extend health span,” reported a “Forbes” artice (https://ibn.fm/s5MWM). “Advances in the development of biomarkers will allow doctors to assess health, quantify the effect of interventions, and produce personalized medical reports.”

Big data plus AI will make neurological care accessible in a way it has not yet been, and BRSF committed to help pave the way.

To learn more about this company, visit www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Asia Broadband Inc. is focused on the production, supply and sale of precious and base metals, primarily to Asian markets
• The company recently acquired a high potential mineral property in the state of Colima, Mexico
• Asia Broadband has teamed with crypto wallet creator Core State Holdings Corp. to develop the AABB Gold token, a gold-backed cryptocurrency coin
• On February 25, 2021, Asia Broadband announced management and board approval of a stock dividend for shareholders

Asia Broadband (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space. Development Program in Colima, Mexico In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property. The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production. Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply. AABB Gold Token In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain. In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.” Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token. AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia. For more information, visit the company’s website at www.AsiaBroadbandInc.com. NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• Archaic technology contributes to dismal recurrence rate in bladder cancer
• Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery
• There is potential to extend this technology to virtually other endoscopic procedures

The battle against cancer is too often set back by crushing blows of recurrence. The disease is insidious. If every single malignant cell of a tumor is not completely removed, it can rebound and attack again. Nowhere is this dismal recurrence more prevalent than in bladder cancer. Caught early, bladder cancer stands a better chance of being successfully treated through surgery and therapeutics. However, bladder cancer has the highest recurrence rate of all cancers. 50% of bladder cancers recur, attacking anew from a just few cells that were missed during surgery. Surgeons do the best they can, but with outdated technology they can’t clearly visualize inside the bladder, clearly identify and then remove potentially malignant cells. This dilemma is about to be rectified with a breakthrough new technology that, will gives surgeons, not only the ability to clearly see inside the bladder, but also more easily identify and surgically remove all the cancer

With bladder cancer as its first target, surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) intends to change the dismal outcomes of bladder cancer recurrence with its i/Blue Imaging(TM) System. The company’s patented, ultrasensitive imaging technology aims to revolutionize the archaic techniques currently used in treating bladder cancer and extend the technology to multiple other surgical procedures.

Conventional diagnostic procedures for visualizing bladder cancer during surgery allow surgeons to see inside the body with a thin, lighted, flexible tube which uses white light to illuminate the bladder. White light images show a full picture of the bladder but do not effectively highlight cancerous cells which can be left behind to attack again. A recent advancement uses blue-filtered white light to better detect tumors and cancerous cells not seen with white light. However, surgeons cannot use blue light images to operate. Blue cystoscope images aren’t in real time and the position in the bladder can be confusing, requiring the surgeon to manually switchback and forth from white to blue light images These technologies remain lacking and recurrence remains at high levels. 600,000 people live in fear that their cancer will return, unfortunately about half of them will have their worst fears realized.

Imagin Medical’s i/Blue Imaging System rectifies the limitations of white and blue light cystoscopies. Combining both the white and blue light with an FDA approved imaging agent, the i/Blue System displays side-by-side images in real-time, eliminating the need to switch back and forth between the two images. Using the i/Blue System, surgeons can now see the full landscape of the bladder and identify malignant cells in a single, unified process. This technological advancement is expected to drive down the dismal recurrence of bladder cancers and deliver hope to the tens of thousands that suffer with the disease.

Imagin Medical’s unique i/Blue Imaging System can attach to virtually any endoscope model currently in use which creates a plug and play system adaptable to almost any clinical setting which opens vast new markets for the company’s technology. The FDA approval process is underway, and the company’s intellectual property is well-protected.

Imagin Medical has reimagined technology to create better outcomes for cancer patients, and as the technology gains traction it may well become the new standard of care for bladder cancer and other endoscopic procedures.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Holding company Clean Power Capital Corp.’s investee PowerTap, a hydrogen fueling innovator, has teamed with carbon energy credits expert Carbonomics to develop and maximize the company’s ability to use clean energy credits
• PowerTap is driven to establish a “hydrogen highway” for environmentally conscious motorists looking for an effective alternative fuel
• Clean Power Capital is a majority investor in PowerTap — a key part of Clean Power’s focus on building up health and renewable energy enterprises
• PowerTap’s next-generation hydrogen stations are also capable of generating electricity to help them continue to pump fuel during a power outage or even potentially power the entire gas stop operation where the fuel stations are located

Holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) advanced its mission of helping health and renewable energy enterprises achieve their growth potential when it became a majority investor in California’s PowerTap Hydrogen Fueling Corp last fall. PowerTap has proven to be a formidable innovator in the clean power industry through its recent agreements with the Andretti Group for fuel station location, marketing and leadership (https://ibn.fm/lF640). Now PowerTap is maximizing its ability to navigate the regulatory hurdles for obtaining certification and emission reduction credits in the United States and international markets by teaming up with Carbonomics, and expert in the process of monetizing carbon credits. “Carbon credits are a key part of every clean energy company’s strategy, and we are pleased to partner with Carbonomics to leverage their expertise and experience to maximize carbon credit revenues,” stated PowerTap CEO Raghu Kilambi (https://ibn.fm/UUvfG). “Leading clean energy companies like Tesla have used emission-reduction credit revenues (https://ibn.fm/K8cBV) to accelerate their growth and cash flow.” PowerTap is preparing to install its 1,250-kilogram hydrogen production and dispensing stations at some of the Andretti Group’s more than 100 retail chain stores, which are focused on fuel, convenience and food operations through facilities under the Chevron, Texaco, Shell, 76, Circle K, Pacific Pride and CFN and other brands. The stations are noteworthy not only for their role in helping to build up a “hydrogen highway” throughout California and eventually into other parts of the country, but also because they are capable of generating electricity. “While much less electricity is needed to produce blue hydrogen vs green hydrogen (https://ibn.fm/39Un2), PowerTap recognized that electricity shortages may affect the operation of its fueling stations,” the company stated in a recent news release acknowledging the power outages in Texas brought on by unusual freezing weather (https://ibn.fm/D9Bd3). “To address this potential issue, PowerTap’s 3rd Generation Onsite Hydrogen fueling unit will have an industrial hydrogen fuel cell that can be used to turn excess hydrogen into electricity that can be used in various capacities including powering further hydrogen production or the rest of the gas/truck stop operations.” PowerTap is a key part of Clean Power Capital’s investment portfolio. Clean Power’s investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in its investments. For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• PlantX Life welcomes new brand ambassadors Venus Williams and Alicia Silverstone
• Plant-based lifestyle allowed Williams to “continue her dreams” as a world-renowned tennis player
• Silverstone chose plant-based two decades ago, calling it “just a healthier way to be”

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has announced world-renowned tennis player Venus Williams and well-known actress Alicia Silverstone as brand ambassadors for the company — a company that Williams noted is “long overdue.” “I can’t tell you how excited I am to be involved, an ambassador, a cheerleader, a stakeholder, and all the above, in PlantX,” said Williams following the announcement, which was made during the company’s annual general meeting (https://ibn.fm/lVSOG). “It’s the first market of its kind, and it’s long overdue.” A former number 1-ranked tennis player with four Olympic gold medals and seven Grand Slam singles titles to her name, Williams first became involved in a plant-based lifestyle 10 years ago when she was diagnosed with an autoimmune disease that threatened to derail her tennis career. At the suggestion of her sister Serena, also a world champion tennis player, Williams committed to a three-week, all-raw vegan program and saw immediate results. “That was my introduction,” she said. “Not only did I learn a lot about food but the food system, and how it fills your body and how we have strayed so far away from where we started as humans and to where we are right now.” Williams noted that a plant-based lifestyle has “become my passion and my hobby, and it’s been able to help me not only get back on tour but also to live a much better quality of life, because when you have a chronic illness, your quality of life goes down. To be able to live a much better quality of life was obviously the first step, and then to be able to continue to live my dreams was the second step.” Silverstone noted similar health benefits when she adopted her vegan lifestyle 20 years ago before many people were even familiar with it, she said, speaking about her enthusiasm for PlantX and her role as a brand ambassador for the Company. Although her primary motivation for choosing a plant-based diet was because she loved animals, she suffered from allergies and wanted to lose weight. “I took on this new way of eating, and I ditched all of that,” she said. “My asthma inhaler went away, my allergy shots went away, my body started to slim down, and this was all by accident. I just did it because I didn’t want to be mean to my dog anymore. . . I made the change but all these amazing health things began to happen. As I did research and started to look at all these studies, it just shows [plant-based] is just a healthier way to be.” Since her decision, Silverstone has become an outspoken advocate for health and wellness, with a particular interest in and support for the plant-based lifestyle. Silverstone and Williams have high praise for PlantX Life, a company that is pioneering its path in the plant-based space. As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, PlantX currently has plans to expand its product lines to include cosmetics, clothing and its own water brand. In addition, the Company uses its digital platform to build a community of like-minded consumers and to provide education. Its successful enterprise is being built and fortified through partnerships with top nutritionists, chefs and brands. For example, the company offers 20 unique pre-made meals designed by top chefs and nutritionists. These healthy meals are offered at extremely competitive prices with fast shipping and round-the-clock convenience. The Company’s commitment to customer service is the driving force behind its e-commerce platform, with innovative thinking driving its operation; the PlantX team is constantly envisioning new ways to collaborate with local restaurateurs and entrepreneurs to bring PlantX to the world. PlantX is committed to eliminating the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit www.PlantX.com, www.PlantX.ca and www.Investor.PlantX.com and view the PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Testing is more important than ever, medical experts claim, urging government to speed up widespread testing
• Tens of millions of rapid, at-home tests may be needed every day
• UME offers rapid testing kits to help end the pandemic, ready to seize the opportunity

The U.S. government has announced plans to roll out more than 60 million home test kits to stop the COVID-19 virus from spreading (https://ibn.fm/O89KJ). United Medical Equipment Business Solutions Network (“UME”), a company offering a comprehensive line of COVID-19 products including rapid testing kits, stands ready to capitalize on the growing push for widespread testing and help slow the global pandemic.

Health experts agree with the new administration’s commitment to widespread rapid testing, but some fear that officials do not respond quickly enough. “Testing is actually more important now than it was eight months ago because of the high contagiousness rate of these new variants,” says Mara Aspinall, a professor of health practice at Arizona State University, said in a recent interview for NPR. “It is critical to stop these new strains right in their tracks. And the only way to do that is to test.”

Identifying infected people through country-wide rapid testing could be vital for curbing the virus and preventing new variants from emerging. The country reportedly needs tens of millions of tests every day to avoid another surge, while it buys time to get enough people vaccinated. “The virus still has an impressive grip on us. We need to be scaling these [tests] up today.”, said Dr. Michael Mina, an infectious disease epidemiologist at the Harvard T.H. Chan School of Public Health, in the article. Dr. Mina urges the Food and Drug Administration to approve more simple, rapid, inexpensive tests. They can be made quickly, thus enabling frequent testing of people at their homes.

Widespread rapid testing could jumpstart testing rates that have been stagnating at 1.6 million a day. At-home tests could make up for shortages in supplies, and the often-long wait times that come with the gold-standard PCR testing.

Other countries have already implemented rapid at-home testing. For example, amid the surge in COVID-19 cases in early 2021, the UK government announced it would roll out millions of cheap, rapid virus tests — a potential game changer in the fight against the virus (https://ibn.fm/ngMgh).

As a company committed to providing essential services during the epidemic, UME offers a comprehensive COVID-19 monitoring toolset designed with the assistance of medical experts. It includes data-driven COVID-19 testing of people with or without symptoms and could be useful for testing those in close contact with someone who has the virus. The Company appears ideally positioned to benefit from the pent-up demand for the rapid test as the push for widespread testing continues to grow.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at  https://ibn.fm/UnitedMed

• Digital subscription platforms have become increasingly popular because they bridge the gap created by closing venues because of the pandemic
• Billboard Bulletin covers the future of live streaming, record labels, and the music industry – citing the experience of Patreon CEO Jack Conte, who has seen exponential growth in the last year
• Friendable’s application Fan Pass has seen 100% growth in live streaming events and artist performances in 2021
• Digital subscription platforms are driven by the superfans and Generation Z social media users and influencers

Although many digital subscription platforms were in existence prior to the monumental impact the pandemic made on the industry in 2020, many did not see unprecedented growth in subscription rates until then. Releasing a digital subscription for fans in 2020, mobile technology and marketing company Friendable (OTC: FDBL) has seen exponential and consistent growth since launching its platform for fans to gain exclusive access to the artists they love. A recent Billboard Bulletin article goes over the future of live streaming, record labels, and the music industry. Available only to paid subscribers at https://ibn.fm/O4JMW, the article quotes Patreon CEO Jack Conte as saying that “the last year has shown artists that subscription platforms are another revenue stream that they can develop in addition to touring and used to offer exclusive content tide to their live shows.” Patreon was founded in 2013 and pioneered the subscription membership platform industry. The company is popular due to its creator-friendly revenue splits. Friendable has already seen a 100% growth in live stream events and artist performances in 2021. In a press release, Friendable’s CEO Robert A. Rositano Jr. said that metrics mean everything – whether they show an increase or a decrease, and that the metrics the company sees guide the teams on the Fan Pass journey (https://ibn.fm/lxN7h). “I am happy to report that Fan Pass is being embraced on all fronts in more ways than I could have imagined,” Rositano Jr. added. “An active community breeds additional activity, content growth and fan engagement, which all feeds the subscription revenue model, artist ticket/event sales and overall merchandise exposure for additional e-commerce revenue. In addition, we believe the convergence of all these advances together will bring Fan Pass closer to attracting its first sponsor and open the door to additional revenue opportunities that are now becoming even clearer.” The Fan Pass platform is a mobile technology and marketing platform designed to help artists engage with their fans worldwide and earn revenue while doing so. Fan Pass brings an “all-access” VIP experience that includes:

• Live performances and online concerts
• Backstage meet & greets before and after the pay-per-view events
• Livestreamed content of studio sessions
• Behind-the-scenes footage of music videos and photoshoots
• Special interviews and one-on-one video
• Streams that highlight the daily lives of the artist

The subscription to the platform starts at $3.99 and provides single-purchase pay-per-view exclusive content like concerts for fans. With the closure of most live music venues worldwide, Fan Pass was designed to help bridge the gap left by the pandemic by enabling connection and engagement between artists and fans. The Billboard Bulletin article also points out that digital subscription platforms that fill the void left by the pandemic are coming off of 12 months of unprecedented subscriber growth due to the high number of artists that joined the platforms. The subscriptions are the equivalent of real-time fan clubs for members of Generation Z who have grown up with micropayments and maintaining multiple subscriptions for media and entertainment. The fan clubs of today are more engaged than they were 20+ years ago when you sent a letter and hoped for an autograph in return. Fans expect exclusive material, VIP tickets, rare merchandise items, and virtual concerts, the article underlines. The reach that subscription platforms have is partially due to the rise of social media and influencers. These have bred the perfect environment to create superfans, which are more impactful thanks to social media use. Artists are inspired and motivated by the superfans because they are often more a part of the artist’s world than the artists themselves. Friendable and Fan Pass are leveraging their success on fans’ desire to gain instant access to the artists they love. Future artists will now cultivate their skills through entrepreneurial qualities, not rely on the traditional record companies to pave a path they can’t recoup from. Revenue streams are readily available through the digital subscription services providing labels and artists access to first-line data that can be used to provide real value and capture a piece of the media budget, the Billboard Bulletin article also notes. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• High Pressure Processing (“HPP”) has become a highly successful method to reduce pathogens and extend shelf-life in food and beverages while maintaining taste, nutrition, flavor, and texture
• The HPP food and beverage market was estimated at $15.5 billion in 2019
• PBI’s UST process combines benefits of HPP with high shear and controlled temperature to achieve effective anti-microbial effects and long-term preservation with reduced or no chemicals
• Academia-Industry partnership will give global food companies in Consortium an early look and first-hand use of UST, with a right to non-exclusively license UST for their own commercial use
• This revolutionary, transformative technology is not just applicable to the massive food and beverage markets, but to the pharmaceutical, nutraceutical, cosmetics, and agriculture markets
• The Consortium resulted from research initially sponsored by the USDA NIFA

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative, pressure-based solutions for the worldwide life sciences and other industries, and the College of Food, Agricultural, and Environmental Sciences (“CFAES”) at The Ohio State University (“Ohio State”) announced a wide-ranging agreement for the implementation of PBI’s patented Ultra Shear Technology(TM) (“UST”) platform. PBI is developing three different models of the UST processing instrument, named the BaroShear: a small footprint benchtop model, a medium capacity floor model, and an industrial scale, continuous flow model for high capacity. All three models are designed to perform high shear processing of liquids under controlled temperatures and pressure conditions. They will be set up for demonstration and hands-on use in the world-renowned Ohio State food pilot plant (https://ibn.fm/BxEdd).

PBI is a leader in development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food/beverage industries. Together with Ohio State, whose CFAES is a globally recognized leader in the food sciences, PBI has formed a food industry consortium to advance the commercialization of its UST platform through the quality enhancement of beverages, condiments, sauces, and other liquid foods. Consortium members will have access to the UST technology in the Ohio State pilot plant and first rights to license all new UST applications developed through the Consortium.

The primary goals of the Consortium are:

• Develop and improve new commercial applications of UST
• Help address potential regulatory issues through scientific support
• Allow global food companies worldwide to experience UST product development and pre-commercialization efforts first-hand

Additionally, Consortium members will be rewarded with “first-look” opportunities to all new UST developments and first rights to non-exclusively license all new applications for commercial purposes.

According to Pressure BioSciences President and CEO Richard T. Schumacher, the Consortium will welcome a global group of preeminent leading food and beverage companies as members. “Each will contribute annually towards the Consortium’s operations, with funds supporting R&D at both PBI and Ohio State while participating as an advisory council to nominate, prioritize and direct UST applications development amongst the myriad opportunities that invite our attention,” he explained.

Food companies worldwide will have access to the Consortium, and members will help direct the scientific effort of OSU and PBI across prospective liquid food and beverage projects. The current topics of interest include:

• Spore inactivation and control of other pathogen and spoilage factors
• Enhancement of taste, smell, and other sensory qualities in liquid foods
• Formation of highly stable products that are suitable for ambient temperature storage, transportation, and distribution

Over the last two decades, high pressure processing (“HPP”) has established itself as a very successful clean-label (reduced or no chemical additives) approach for food safety and improved product life, according to PBI Senior Vice President of Engineering Dr. Edmund Y. Ting. As a result, the high pressure processing (“HPP”) food market reached $15.5 billion in 2019 and is expected to increase substantially through 2025 (https://ibn.fm/sY5RY). The HPP market makes some (not all) food safer, more stable, more nutritious, better tasting, and with fewer chemicals (clean label).

According to Dr. Edmund Ting, Sr. VP of Engineering at PBI and a pioneer in the development of HPP, “HPP has proven to be very effective in reducing food-borne pathogens and extending shelf-life in pre-packaged foods (e.g., juices and ready-to-eat meats), thus eliminating the need for chemical additives. However, because it is only a pasteurization process, and does not render food “commercially sterile”, HPP-processed food must be shipped, stored, and maintained under refrigeration throughout the entire chain of distribution and retail sale. We believe that Ultra Shear Technology will provide economical solutions to these problems, and will offer an additional, clean label processing choice to both consumers and the food industry around the world.”

The potential of UST is not just limited to food and beverages. Through this revolutionary platform, vitamins and cannabinoids could be infused into beverages, remaining in them without precipitating out, as is often seen today. Gels, creams, ointments, and other lotions could penetrate the skin faster and more completely, bringing the active ingredient to where it needs to be faster and with higher bioavailability. Vaccines and therapeutics could be enhanced and improved. The applications and benefits are seemingly endless.

PBI and Ohio State gratefully acknowledge the initial research support by the USDA NIFA, which resulted in the Consortium.

For more information, visit the company’s website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO